



## **Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024**

September 17, 2024

*Late-breaking oral presentation will discuss the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways*

*ZL-1503 is part of Zai Lab's internally discovered and developed global pipeline*

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 17, 2024-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; "Zai Lab") today announced that data from a preclinical study of ZL-1503, the company's internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Netherlands. The results will address the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis, as well as other diseases involving the IL-13 and IL-31 pathways.

Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. However, certain AD symptoms are mediated by IL-31, which is only partially attenuated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications. Zai is evaluating the potential of ZL-1503 to inhibit both IL-13 and IL-31 signaling pathways.

"The potential to simultaneously target both inflammatory and pruritogenic pathways is important as it expands treatment options for individuals with atopic dermatitis and other related conditions," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "We look forward to sharing preliminary results from our preclinical study of ZL-1503 at EADV 2024."

### **Details regarding the ZL-1503 oral presentation at EADV 2024 are as follows:**

**Title:** ZL-1503, a Bispecific, Serum Half-life Extended Antibody Targeting Both Inflammatory and Pruritogenic Pathways for Atopic Dermatitis and Other IL-13/IL-31 Related Diseases

**Abstract Number:** 7744

**Presenter:** Dr. Manuel Pereira, MD/PhD, Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany

**Presentation date and time:** Thursday, September 26, 2024, 2:15-2:30 p.m. CEST

**Session code and title:** D2T01.3AA: Late Breaking News

**Session room:** Auditorium

### **About Zai Lab**

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit [www.zailaboratory.com](http://www.zailaboratory.com) or follow us at [www.twitter.com/Zai\\_lab\\_Global](https://www.twitter.com/Zai_lab_Global).

### **Zai Lab Forward-Looking Statements**

This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding product candidates in our pipeline including ZL-1503 and related preclinical studies; the potential benefits of ZL-1503; and the potential treatment of atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,

including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Our SEC filings can be found on our website at [www.zailaboratory.com](http://www.zailaboratory.com) and the SEC's website at [www.sec.gov](http://www.sec.gov).



View source version on [businesswire.com](https://www.businesswire.com/news/home/20240917669591/en/): <https://www.businesswire.com/news/home/20240917669591/en/>

**Investor Relations:**

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

[christine.chiou1@zailaboratory.com](mailto:christine.chiou1@zailaboratory.com) / [lina.zhang@zailaboratory.com](mailto:lina.zhang@zailaboratory.com)

**Media:**

Shaun Maccoun/ Xiaoyu Chen

+1 (857) 270-8854 / +86 185 0015 5011

[shaun.maccoun@zailaboratory.com](mailto:shaun.maccoun@zailaboratory.com) / [xiaoyu.chen@zailaboratory.com](mailto:xiaoyu.chen@zailaboratory.com)

Source: Zai Lab Limited